1.42
1.42 (0%)
As of Feb 14, 2025
Fate Therapeutics Inc [FATE]
Source:
Company Overview
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of off-the-shelf cellular immunotherapies to patients.
| Country | United States |
| Headquarters | san diego, california |
| Phone Number | (858) 875-1800 |
| Industry | manufacturing |
| CEO | J. Scott Wolchko |
| Website | www.clinicaltrials.gov |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $13.6 |
| Operating Profit | $-210.3 |
| Net Income | $-186.3 |
| Net Cash | $-10.8 |
Profit Ratios
| Gross Margin | $13.6 |
| Operating Margin | -1,542.6 |
| Profit as % of Revenues | -7.3% |
| Profit as % of Assets | -39.3% |
| Profit as % of Stockholder Equity | -58.4% |
Management Effectiveness
| Return on Equity | -58.4% |
| Return on Assets | -42.3% |
| Turnover Ratio | 2.9% |
| EBITA | $-210.3 |
Balance Sheet and Cash Flow Measures
| Total Assets | $440.7 |
| Total Liabilities | $122 |
| Operating Cash Flow | $-122.9 |
| Investing Cash Flow | $12.2 |
| Financing Cash Flow | $99.9 |
